Biomarkers and Key Drivers of Drug Development in Gene Therapy

In order to precisely, efficiently, and safely treat patients, biomarkers must be properly identified and used. They are instruments that can ease the selection and monitoring of gene therapies. There are numerous biomarkers for disease, immunological, cellular, and molecular responses to gene therapies, and their use will increase as gene therapies advance. Drug discovery depends on choosing the right patient for the correct therapy and tracking that patient's response to the therapy. Biotechnology and pharmaceutical companies must implement suitable selection and monitoring methods in order to offer patients the safest and most effective therapeutic options for genetic diseases in light of the gene therapy industry's explosive growth. The use of precision medicine is transforming how we diagnose, treat, and monitor many diseases.


In blood or tissue samples, biological molecules can be identified, such as enzymes (biological agents that alter the body and quicken or catalyse chemical reactions) (for example, in the case of cancer).


Genetic modifications include DNA methylation, which refers to specific chemical changes that some genes or DNA sequences go through, and which govern whether or not they are expressed as proteins, the amount of expression of particular genes, etc.


Medical imaging: magnetic resonances (MRI)) or radiographies. By using computational models, quantitative parameters are derived from radiological images.


Come hear our speakers discuss Biomarkers and Key Drivers of Drug Development in Gene Therapy on March 28–29, 2023 at the International Bioprocessing and Biologics Forum in Steigenberger Airport Hotel, Berlin, Germany. They will also discuss the state of continuous process implementation at the moment and some ongoing challenges.


To register or learn more about the Forum please check here:


For more information and group participation, contact us: [email protected]